3386 COSMO BIO COMPANY, LIMITED - Financial Results

About Information Provided on This Site

The information provided on our website 'Kabutan.com' is not intended to constitute investment solicitation or investment advisory services.
All investment decisions should be made at your own discretion and judgment.
The data on our website is provided by Tokyo Stock Exchange, Osaka Exchange, Nagoya Securities Exchange, JPX Market Innovation & Research, Japannext, and other sources.
Copyright of the Nikkei Stock Average belongs to Nikkei Inc. Stock price charts displayed on Kabutan.com are provided solely for the purpose of reviewing historical price movements of the securities.
These charts neither suggest nor guarantee future price movements of the securities and do not constitute recommendations to buy or sell.
In our financial results coverage, the term 'Surprise Results' identifies securities that demonstrate a significant degree of surprise in their earnings announcements.
This significance is quantitatively assessed based on multiple factors, including: the nature of the announcement (full-year or quarterly results); types of revisions (earnings or dividend forecasts); and numerical analysis comparing the announced results with both the company's previous forecasts and historical performance.
The 'Surprise Ranking' presents these results in order of their calculated surprise factor. Please note that neither these results nor rankings are intended to suggest or guarantee future performance of the listed securities, nor should they be construed as recommendations to buy or sell.

3386

TSE Standard

COSMO BIO COMPANY, LIMITED

1,334

JPY

-7

(-0.52%)

Mar 13, 3:30 pm JST

8.36

USD

Mar 13, 2:30 am EDT

Result

PTS

outside of trading hours

ー

Summary Chart Historical News Financial Result

Current Period Guidance

Annual

Result

Guidance History

Growth Rate

Profitability

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Adj. Dividend	Announce	Accounting Standards
Dec, 2022	9,553	816	790	517	89.1	36	Feb 14, 2023	J-GAAP
Dec, 2023	9,340	519	653	442	76.0	30	Feb 14, 2024	J-GAAP
Dec, 2024	10,037	318	364	262	45.1	50	Feb 14, 2025	J-GAAP
Dec, 2025	10,766	343	489	337	59.3	50	Feb 13, 2026	J-GAAP
Dec, 2026 Guidance	11,400	270	340	220	38.8	50	Feb 13, 2026	J-GAAP
YoY	+5.9%	-21.3%	-30.5%	-34.7%	-34.6%

Revision Direction	Revision Date	Revenue	Operating Profit	Ordinary Profit	Net Profit	Revised Dividend	Accounting Standards
Dec, 2021	Feb 12, 2021	8,200	700	750	480	26	J-GAAP
	Jul 27, 2021	9,000	900	950	630	26	J-GAAP
	Dec 16, 2021	9,000	900	950	630	36	J-GAAP
Results	Feb 14, 2022	9,231	1,048	1,099	737	36	J-GAAP
Dec, 2022	Feb 14, 2022	Available in future release
	Jul 25, 2022
Results	Feb 14, 2023
Dec, 2023	Feb 14, 2023
Results	Feb 14, 2024
Dec, 2024	Feb 14, 2024
	Aug 5, 2024
Results	Feb 14, 2025
Dec, 2025	Feb 14, 2025
Results	Feb 13, 2026
Dec, 2026	Feb 13, 2026	11,400	270	340	220	50	J-GAAP

Fiscal Year	Revenue	YoY	Operating Profit	YoY	Ordinary Profit	YoY	Adj. EPS	YoY
Dec, 2001	4,181	+40.1	Available in future release
Dec, 2002	4,527	+8.3
Dec, 2003	4,810	+6.3
Dec, 2004	4,970	+3.3
Dec, 2005	5,498	+10.6
Dec, 2006	5,936	+8.0
Dec, 2007	5,906	-0.5
Dec, 2008	5,622	-4.8
Dec, 2009	5,282	-6.0
Dec, 2010	6,676	+26.4
Dec, 2011	7,192	+7.7
Dec, 2012	7,241	+0.7
Dec, 2013	7,050	-2.6
Dec, 2014	7,235	+2.6
Dec, 2015	7,357	+1.7
Dec, 2016	7,427	+1.0
Dec, 2017	7,068	-4.8
Dec, 2018	7,261	+2.7
Dec, 2019	7,590	+4.5
Dec, 2020	8,092	+6.6
Dec, 2021	9,231	+14.1
Dec, 2022	9,553	+3.5
Dec, 2023	9,340	-2.2
Dec, 2024	10,037	+7.5
Dec, 2025	10,766	+7.3
Dec, 2026 Guidance	11,400	+5.9	270	-21.3	340	-30.5	38.8	-34.6

Fiscal Year	Revenue	Operating Profit	Operating Profit Margin	ROE	ROA	Total Asset Turnover Ratio	Adj. EPS
Dec, 2024	10,037	318	3.17	3.01	2.32	0.89	45.1
Dec, 2025	10,766	343	3.19	3.68	2.76	0.88	59.3
Dec, 2026 Guidance	11,400	270	2.37	2.35	1.74	0.90	38.8

All-Time High

	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS
Record	10,766	1,048	1,099	737	126.9
Fiscal Year	Dec, 2025	Dec, 2021	Dec, 2021	Dec, 2021	Dec, 2021

First Half

Result

Guidance History

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Adj. Dividend	Announce	Accounting Standards
Jan - Jun, 2023	4,827	458	552	361	62.0	14	Aug 4, 2023	J-GAAP
Jan - Jun, 2024	5,129	322	337	258	44.2	14	Aug 5, 2024	J-GAAP
Jan - Jun, 2025	5,402	276	343	250	44.0	25	Aug 5, 2025	J-GAAP
Jan - Jun, 2026 Guidance	5,700	170	200	130	22.9	25	Feb 13, 2026	J-GAAP
YoY	+5.5%	-38.4%	-41.7%	-48.0%	-48.0%

Revision Direction	Revision Date	Revenue	Operating Profit	Ordinary Profit	Net Profit	Revised Dividend	Accounting Standards
Jun, 2023	Feb 14, 2023	5,200	440	490	330	14	J-GAAP
Results	Aug 4, 2023	4,827	458	552	361	14	J-GAAP
Jun, 2024	Feb 14, 2024	Available in future release
Results	Aug 5, 2024
Jun, 2025	Feb 14, 2025
Results	Aug 5, 2025
Jun, 2026	Feb 13, 2026	5,700	170	200	130	25	J-GAAP

Cash Flow

Annual

Fiscal Year	Operating Profit	Fee Cash Flow	Operating Cash Flow	Investing Cash Flow	Financial Cash Flow	Cash & Equivalents	Cash Ratio	Accounting Standards
Dec, 2023	519	-22	736	-758	-201	2,826	25.99	J-GAAP
Dec, 2024	318	24	241	-217	-479	2,393	20.41	J-GAAP
Dec, 2025	343	638	595	43	-283	2,747	21.69	J-GAAP

Actual Performance and Financial Trends

Historical Performance

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Adj. Dividend	Announce	Accounting Standards
Dec, 2023	9,340	519	653	442	76.0	30	Feb 14, 2024	J-GAAP
Dec, 2024	10,037	318	364	262	45.1	50	Feb 14, 2025	J-GAAP
Dec, 2025	10,766	343	489	337	59.3	50	Feb 13, 2026	J-GAAP
YoY	+7.3%	+7.9%	+34.3%	+28.6%	+31.5%

Quarterly Results

Result

Growth Rate

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Operating Profit Margin	Announce	Accounting Standards
Jan - Mar, 2024	2,943	305	299	230	39.6	10.4	May 9, 2024	J-GAAP
Apr - Jun, 2024	2,186	17	38	28	4.8	0.8	Aug 5, 2024	J-GAAP
Jul - Sep, 2024	2,280	47	47	33	5.7	2.1	Nov 7, 2024	J-GAAP
Oct - Dec, 2024	2,628	-51	-20	-29	-5.0	-1.9	Feb 14, 2025	J-GAAP
Jan - Mar, 2025	3,093	273	293	212	37.2	8.8	May 9, 2025	J-GAAP
Apr - Jun, 2025	2,309	3	50	38	6.7	0.1	Aug 5, 2025	J-GAAP
Jul - Sep, 2025	2,483	-1	26	22	3.9	0.0	Nov 7, 2025	J-GAAP
Oct - Dec, 2025	2,881	68	120	65	11.4	2.4	Feb 13, 2026	J-GAAP
YoY	+9.6%	－	－	－	－

Fiscal Year	Revenue	YoY	Operating Profit	YoY	Ordinary Profit	YoY	Adj. EPS	YoY
Jan - Mar, 2021	2,878	+18.9	Available in future release
Apr - Jun, 2021	1,957	+28.2
Jul - Sep, 2021	2,046	+8.8
Oct - Dec, 2021	2,350	+3.7
Jan - Mar, 2022	3,047	+5.9
Apr - Jun, 2022	2,064	+5.5
Jul - Sep, 2022	2,016	-1.5
Oct - Dec, 2022	2,426	+3.2
Jan - Mar, 2023	2,828	-7.2
Apr - Jun, 2023	1,999	-3.1
Jul - Sep, 2023	2,050	+1.7
Oct - Dec, 2023	2,463	+1.5
Jan - Mar, 2024	2,943	+4.1
Apr - Jun, 2024	2,186	+9.4
Jul - Sep, 2024	2,280	+11.2
Oct - Dec, 2024	2,628	+6.7
Jan - Mar, 2025	3,093	+5.1
Apr - Jun, 2025	2,309	+5.6
Jul - Sep, 2025	2,483	+8.9
Oct - Dec, 2025	2,881	+9.6	68	－	120	－	11.4	－

All-Time High Quarterly Results

	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS
Record	3,093	578	565	366	63.2
Fiscal Year	Mar, 2025	Mar, 2022	Mar, 2022	Mar, 2022	Mar, 2022

Key Balance Sheet Figures

Fiscal Year	BPS	Equity Ratio	Total Asset	Equity	Retained Earnings	Announce	Accounting Standards
Dec, 2023	1,447.08	77.7	10,872	8,444	5,805	Feb 14, 2024	J-GAAP
Dec, 2024	1,565.00	76.5	11,723	8,967	5,891	Feb 14, 2025	J-GAAP
Dec, 2025	1,652.02	74.0	12,662	9,373	5,880	Feb 13, 2026	J-GAAP

COSMO BIO COMPANY, LIMITED(3386) Financial Results